查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1198165

射頻消融設備市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Radiofrequency Ablation Devices Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在 2022 年至 2027 年的研究期間，射頻消融設備市場預計將以 10.4% 的複合年增長率顯著增長。

COVID-19 大流行影響了世界各地的醫療保健系統，擾亂了許多醫療機構的正常護理，並使易受傷害的癌症患者面臨重大風險。 例如，2020 年發布的“COVID-19 大流行對癌症治療的影響：一項全球合作研究”包括 2020 年 4 月 21 日至 5 月 8 日期間參與的 6 大洲 54 個國家/地區。根據對 356 個設施的調查，一些挑戰在提供癌症護理方面已有報導。 這些設施每年為 716,979 名新癌症患者提供服務。 大多數 (88.2%) 報告在大流行期間提供護理方面存在挑戰。 作為先發製人戰略的一部分，55.34% 的中心縮減了服務，其他常見原因是系統超載 (19.94%)、缺乏個人防護設備 (19.10%) 和工作人員不足 (17.98%)，以及藥物獲取受限(9.83%)。 此外，在 COVID-19 大流行高峰期間，房顫 (AF) 的導管消融手術顯著縮減，以節省醫療資源並減少輻射暴露。 根據 2021 年 2 月發表的“在 COVID-19 大流行中重啟心房顫動消融”研究，研究對像中沒有因消融而感染 COVID-19 的病例。 然而，儘管 2020 年持續性心律失常的患病率很高，但與 2019 年相比，進行的經食管超聲心動圖檢查較少，醫療資源被重新用於 COVID-19 護理。 結果，消融手術的數量減少，這對市場產生了負面影響。 因此，大流行的早期對市場增長率產生了重大影響。 然而，隨著世界各地的一些選擇性和癌症治療已恢復到大流行前的水平，預計市場將獲得更多牽引力。

推動市場增長的因素包括微創手術的普及、慢性病負擔的增加以及老年人口的增加。 例如，根據 GLOBOCAN 2020 的 2020 年統計數據，2020 年有 19,292,789 人被診斷出患有癌症。 同樣的數據估計，2040年癌症患者人數將達到3020萬。 因此，癌症患病率的增加表明對有效的癌症微創手術的需求不斷增長，從而推動了對射頻消融設備的需求。

此外，產品發布、合併、收購和合作夥伴關係等戰略舉措將帶來利潤豐厚的市場增長。 例如，2022年3月，Shijiazhuang Speedin Instruments推出了射頻信號發生器，這是一種專門用於載波測試的射頻信號發生器。

此外，不斷增加的研究和開發證明了市場上現有產品的功效，預計將進一步促進市場增長。 例如，2022 年 1 月發表的論文“下一代導管縮短 AF 消融時間”評估了 Biosense-Webster 的 Qdot Micro 導管，將溫控消融與接觸力的 3D 電解剖映射相結合。它已被證明是一種靈敏的射頻消融導管。 該導管提供高能量消融、改進的溫度監測、優化的沖洗和高信號分辨率，可幫助醫生通過簡單的工作流程縮短手術時間。 射頻消融設備的這些優勢有望增強其適應性，從而推動市場增長。 此外，2022 年 2 月，Ramesh 醫院將在印度維傑亞瓦達開設一個現代化的心臟電生理學實驗室，該實驗室將採用射頻消融、起搏器和自動植入式心律轉復除顫器等新療法。 預計此類舉措將增加對高頻治療設備的需求並推動市場增長。

因此，由於上述因素，該研究涵蓋的市場預計在研究期間將顯著增長。 然而，替代療法的低意識和可用性以及高昂的治療成本預計將阻礙預測期內的市場增長。

高頻消融設備市場趨勢

市場細分預計在預測期內佔最大份額

腫瘤科在高頻消融設備市場佔有很大份額。 全球範圍內越來越多的癌症患者正在推動該細分市場的增長。 例如，2021 年 9 月世界衛生組織 (WHO) 的最新消息指出，癌症已在全球範圍內奪去約 1000 萬人的生命。 2020年最常見的癌症（根據新增癌症患者人數）依次為乳腺癌（226萬）、肺癌（221萬）、結直腸癌（193萬）、前列腺癌（141萬）、皮膚癌（非黑色素瘤）（1.2萬）和胃（109 萬）。 這種病例數的同比增長極大地促進了手術治療的有效治療，從而推動了對消融設備的需求。

此外，根據 2021 年 2 月更新的 RadiologyInfo.org 文章，射頻消融 (RFA) 是一種微創癌症治療方法，它使用圖像引導技術加熱來殺死癌細胞。它具有破壞性。 RFA利用超聲波、CT（計算機斷層掃描）、MRI（磁共振成像）等將針狀電極引導至癌性腫瘤，通過電極，高頻電流通過放置在其上的接地墊身體，它會產生集中的熱量，破壞電極周圍的癌細胞。 該文章還表明，射頻和微波消融治療是癌症治療中最常用的方式。

此外，增加研發投入也將提高射頻消融設備在治療各類癌症方面的可用性，從而加速該細分市場的增長。 例如，杭州市第一人民醫院於 2020 年發表了一項題為“內窺鏡射頻消融術 (RAF) 聯合吉西他濱和 S-1 治療無法切除的膽管癌患者：一項隨機、開放標籤臨床試驗”的研究。該研究於 1 月開始2020年，將比較RAF聯合吉西他濱和S-1治療不可切除膽管癌的療效和安全性。 該試驗預計將於 2022 年 6 月完成。 因此，此類做法的良好結果將刺激這一領域的增長。

因此，預計研究部門在分析期間將實現有利增長。

北美佔據了很大的市場份額，預計在預測期內也會如此

北美射頻 (RF) 消融設備市場增長的主要驅動力是慢性病患病率的增加、微創手術需求的增加、產品發布的增加以及主要市場參與者的戰略主動性的提高。 預計在預測期內，美國將佔據北美地區研究市場的很大份額。 例如，據2022年美國癌症協會估計，2022年全國將診斷出約236,740例肺癌新病例。 該文件還指出，到 2022 年，將報告 79,000 例腎癌新病例和 13,920 例死亡病例。 因此，癌症的高負擔有望增加對消融設備的需求，從而推動市場增長。

此外，主要市場參與者採取的戰略舉措（例如產品發布、合作夥伴關係、新計劃、併購）預計將推動市場增長。 例如，2021 年 2 月，美國食品和藥物管理局批准Medtronic的 DiamondTemp 沖洗消融導管用於治療對射頻心臟消融空間內的藥物治療無反應的複發性心房顫動患者。

此外，在 2020 年 11 月，Abbott推出了 IonicRF 發生器，該發生器有望提供一種非手術、微創治療來治療神經性疼痛。 IonicRF 發生器是一種射頻消融設備，它使用熱量來瞄準特定神經並阻止疼痛信號到達大腦。 因此，推出此類產品將擴大公司的產品供應和地理足跡，推動預測期內的市場增長。

因此，上述這些因素預計將在未來幾年推動該地區市場的增長。

高頻消融器械市場競爭者分析

市場由大公司主導，競爭溫和。 主要參與者有 Avanos Medical Inc.、Stryker、Abbottt、Medtronic、Boston Scientific Corporation 等。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 越來越喜歡微創手術
    • 慢性病患病率增加
  • 市場製約因素
    • 對替代療法的認識和可用性較低
    • 高昂的治療費用
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：100 萬美元）

  • 按產品類型
    • 高頻發生器
    • 消耗品
  • 通過申請
    • 腫瘤科
    • 心髒病學和心率管理
    • 婦科
    • 疼痛管理
    • 其他應用
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Avanos Medical, Inc.
    • Stryker
    • Abbottt
    • Medtronic
    • Boston Scientific Corporation
    • Becton, Dickinson and Company（Venclose, Inc.）
    • AngioDynamics, Inc.
    • Hologic, Inc.
    • AtriCure, Inc.
    • Koninklijke Philips N.V.
    • Smith+Nephew
    • Baylis Medical Company, Inc

第七章市場機會與未來趨勢

簡介目錄
Product Code: 90538

The Radiofrequency Ablation Devices market is expected to grow at a significant CAGR of 10.4% during the study period, 2022-2027.

The COVID-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks. For instance, a study titled "Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study" published in 2020 reported that there were several challenges in delivering cancer care based on a survey of a total of 356 centers from 54 countries across six continents that participated between April 21 and May 8, 2020. These centers serve 716,979 new patients with cancer every year. Most of them (88.2%) reported facing challenges in delivering care during the pandemic. Although 55.34% of the centers reduced their services as part of a preemptive strategy, other common reasons included an overwhelmed system (19.94%), lack of personal protective equipment (19.10%), staff shortage (17.98%), and restricted access to medications (9.83%). Moreover, catheter ablation procedures for atrial fibrillation (AF) were significantly curtailed during the peak of the COVID-19 pandemic to conserve healthcare resources and limit exposure. According to the study "Rebooting atrial fibrillation ablation in the COVID-19 pandemic," published in February 2021, there were no cases of ablation-related COVID-19 transmission in the study population. However, there were a smaller number of transesophageal echocardiography procedures performed in 2020 as compared to 2019 despite a greater prevalence of persistent arrhythmia in 2020, indicating that healthcare resources were reutilized for COVID-19 care. As a result, fewer ablation procedures were performed, thereby negatively impacting the market. Thus, such circumstances greatly affected the market's growth rate throughout the initial pandemic phase. However, the market is anticipated to gain traction as several elective and cancer care procedures have resumed to pre-pandemic levels across the globe.

The factors propelling the studied market growth are the increasing prevalence of minimally invasive procedures, the growing burden of chronic diseases, and the senior population. For instance, as per the 2020 statistics by GLOBOCAN 2020, 19,292,789 people were diagnosed with cancer in 2020. According to the same source, the number of people with cancer is estimated to reach 30.2 million by 2040. Thus, increasing cancer prevalence indicates a rising need for effective minimally invasive surgical procedures for cancer, thereby driving the demand for radiofrequency ablation devices.

Additionally, strategic initiatives such as product launches, mergers, acquisitions, partnerships, and others will lead to lucrative market growth. For instance, in March 2022, Shijiazhuang Suin Instruments Co., Ltd. launched an RF signal generator, an instrument that's especially used to produce RF signals for carrier tests.

Furthermore, the rising research and development studies proving the efficacies of existing products in the market are expected to further contribute to the market's growth. For instance, the article "Next-generation catheter cuts AF ablation time," published in January 2022, evaluated the Biosense Webster's Qdot Micro catheter and demonstrated that it is a contact force-sensing radiofrequency ablation catheter with temperature-controlled ablation and 3D electroanatomical mapping integration. It incorporated advanced, high-energy ablation, improved temperature monitoring, optimized irrigation, and higher signal resolution, providing physicians with a simplified workflow that helps shorten procedure time. These advantages of radiofrequency ablation devices are expected to increase their adaptability, thereby driving the market growth. Moreover, in February 2022, Ramesh hospitals launched a modernized cardiac electrophysiology lab in Vijayawada, India, which will incorporate new therapies such as radio frequency ablation, pacemakers, automatic implantable cardiac defibrillators, and others. Thus, such initiatives will increase the demand for radio frequency devices, thereby driving the market growth.

Therefore, owing to the factors above, the studied market is expected to grow significantly during the study period. However, low awareness and availability of alternative treatment methods and high treatment costs are expected to hinder the market's growth during the forecast period.

Radiofrequency Ablation Devices Market Trends

Oncology Segment is Expected to Account for the Largest Market Share During the Forecast Period

The oncology segment holds a major share of the radiofrequency ablation devices market. The rising number of cancer cases around the world is adding to segmental growth. For example, a September 2021 World Health Organization (WHO) update stated that cancer resulted in approximately 10 million deaths worldwide. The most common cancers in 2020 (according to new cancer cases) were: breast cancer (2.26 million cases); lungs (2.21 million cases); colon and rectum (1.93 million cases); prostate (1.41 million patients); skin (non-melanoma) (1.20 million cases); and stomach (1.09 million cases). This increase in the number of cases over the years is majorly contributing to the increase in surgical therapies for efficient treatments, which in turn will propel the demand for ablation devices.

Furthermore, according to an article published by RadiologyInfo.org updated in February 2021, radiofrequency ablation (RFA), a minimally invasive treatment for cancer, employs an image-guided technique to apply heat to destroy cancer cells. RFA uses ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) to guide a needle electrode into a cancerous tumor and passes high-frequency electrical currents through the electrode to ground pads placed on the body, thereby creating focused heat that destroys the cancer cells surrounding the electrode. The article also suggested that radio frequency and microwave ablations are the most commonly used ablation treatment methods for cancer therapy.

In addition, the growing investment in research and development will also increase the availability of radiofrequency ablation devices in the treatment of various types of cancer, thereby accelerating the segment's growth. For example, the study titled "Endoscopic Radiofrequency Ablation (RAF) Combined With Gemcitabine and S-1 in Patients for Unresectable Cholangiocarcinoma: A Randomized Open-Labeled Clinical Trial" was initiated in January 2020 by the First People's Hospital of Hangzhou to compare the efficacy and safety of RAF combined with Gemcitabine and S-1 in patients with unresectable cholangiocarcinoma. This study is expected to be completed by June 2022. Therefore, the positive results from such practices will spur the segment's growth.

Therefore, the studied segment is expected to project lucrative growth over the analysis period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same over the Forecast Period

The primary driving factors for the growth of the North American radiofrequency (RF) ablation devices market are the increasing prevalence of chronic diseases; increasing demand for minimally invasive surgeries; increasing product launches; and rising strategic initiatives by key market players. The United States is expected to hold a significant share in the studied market in the North American region during the forecast period. For instance, according to the estimates of the 2022 American Cancer Society, Inc., about 236,740 new cases of lung cancer will be diagnosed in the country in 2022. The same source also stated that 79,000 new cases and 13,920 deaths will be reported in 2022 from kidney cancer. Thus, the high burden of cancer is expected to boost the demand for ablation devices, thereby driving the market growth.

Moreover, strategic initiatives undertaken by the key market players, such as product launches, partnerships, new programs, mergers, and acquisitions, are likely to drive market growth. For instance, in February 2021, the Food and Drug Administration approved Medtronic's DiamondTemp irrigated ablation catheter in the RF cardiac ablation space, designed to treat patients with recurrent atrial fibrillation that has not responded to drug therapies.

Furthermore, in November 2020, Abbott launched the IonicRF Generator, which is expected to deliver a non-surgical, minimally invasive treatment for managing pain in the nervous system. The IonicRF Generator is a radiofrequency ablation device that uses heat to target specific nerves and block pain signals from reaching the brain. Thus, launching such products will expand the company's offerings and geographical footprint, driving market growth over the forecast period.

Thus, these aforementioned factors are anticipated to boost the growth of the market in the region over the coming years.

Radiofrequency Ablation Devices Market Competitor Analysis

The market is moderately competitive with major players dominating the market. The major players in the market are Avanos Medical Inc., Stryker, Abbott, Medtronic, Boston Scientific Corporation, and Others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Preference for Minimally Invasive Procedures
    • 4.2.2 Increasing Prevalence of Chronic Diseases
  • 4.3 Market Restraints
    • 4.3.1 Low awareness and availability of alternative treatment method
    • 4.3.2 High treatment cost
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Product Type
    • 5.1.1 Radiofrequency Generators
    • 5.1.2 Consumables
  • 5.2 By Application
    • 5.2.1 Oncology
    • 5.2.2 Cardiology and Cardiac Rhythm Management
    • 5.2.3 Gynecology
    • 5.2.4 Pain Management
    • 5.2.5 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Avanos Medical, Inc.
    • 6.1.2 Stryker
    • 6.1.3 Abbott
    • 6.1.4 Medtronic
    • 6.1.5 Boston Scientific Corporation
    • 6.1.6 Becton, Dickinson and Company (Venclose, Inc.)
    • 6.1.7 AngioDynamics, Inc.
    • 6.1.8 Hologic, Inc.
    • 6.1.9 AtriCure, Inc.
    • 6.1.10 Koninklijke Philips N.V.
    • 6.1.11 Smith+Nephew
    • 6.1.12 Baylis Medical Company, Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS